Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.69 |
| ▸ | JAK1 | P23458 | 13/20 | 0.69 |
| ▸ | JAK3 | P52333 | 4/20 | 0.69 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.69 |
| ▸ | PAK4 | O96013 | 2/20 | 0.69 |
| ▸ | ABL1 | P00519 | 2/20 | 0.69 |
| ▸ | RET | P07949 | 2/20 | 0.69 |
| ▸ | LTK | P29376 | 2/20 | 0.69 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.69 |
| ▸ | CLK2 | P49760 | 2/20 | 0.69 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.69 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.69 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.69 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.69 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.69 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.69 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.69 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.69 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 0.69 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rovadicitinib SCHEMBL17858806 | 1.00 | JAK2 (0.69) | JAK2JAK1JAK3DAPK3PAK4 | |
| Rovadicitinib SCHEMBL17858797 | 1.00 | JAK2 (0.69) | JAK2JAK1JAK3DAPK3PAK4 | |
| SCHEMBL31734179 | 0.99 | JAK2 (0.68) | JAK2JAK1JAK3DAPK3PAK4 | |
| SCHEMBL31734171 | 0.99 | JAK2 (0.68) | JAK2JAK1JAK3DAPK3PAK4 | |
| SCHEMBL31734169 | 0.99 | JAK2 (0.68) | JAK2JAK1JAK3DAPK3PAK4 | |
| Rovadicitinib SCHEMBL19466579 | 0.99 | JAK2 (0.68) | JAK2JAK1JAK3DAPK3PAK4 | |
| Rovadicitinib SCHEMBL19466578 | 0.99 | JAK2 (0.68) | JAK2JAK1JAK3DAPK3PAK4 | |
| SCHEMBL31734157 | 0.98 | JAK2 (0.66) | JAK2JAK1JAK3DAPK3PAK4 | |
| SCHEMBL31734164 | 0.98 | JAK2 (0.66) | JAK2JAK1JAK3DAPK3PAK4 | |
| SCHEMBL31734162 | 0.98 | JAK2 (0.66) | JAK2JAK1JAK3DAPK3PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133735-A1 | USE OF PYRROLOPYRIMIDINE COMPOUND FOR TREATING HEMOPHAGOCYTIC SYNDROME | CHIA TAI TIANQING PHARMACEUTICAL CO. ,LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-4119562-A1 | USE OF PYRROLOPYRIMIDINE COMPOUND FOR TREATING HEMOPHAGOCYTIC SYNDROME | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-01-18 | — | — | EP | disclosed |
| WO-2022268083-A1 | USE OF PYRROLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE | 正大天晴药业集团股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-20220072002-A1 | TREATMENT USE OF PYRROLOPYRIMIDINE COMPOUND, AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND | CHIA TAI TIANQING PHARMACEUTICALGROUP CO., LTD. (CN) | 2022-03-10 | — | — | US | disclosed |
| CN-111875607-B | Preparation method of chiral pyrrolopyrimidine compound | 正大天晴药业集团股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-111018861-B | Pyrrolopyrimidine compounds | 正大天晴药业集团股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3904356-A1 | TREATMENT USE OF PYRROLOPYRIMIDINE COMPOUND, AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-11-03 | — | — | EP | disclosed |
| EP-3473626-B1 | PYRROLOPYRIMIDINE CRYSTAL FOR PREPARING JAK INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3473626-B1 | PYRROLOPYRIMIDINE CRYSTAL FOR PREPARING JAK INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3473625-B1 | PREPARATION METHOD FOR CHIRAL PYRROLOPYRIMIDINE COMPOUND | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-06-02 | — | — | EP | disclosed |
| EP-3473625-A1 | PREPARATION METHOD FOR CHIRAL PYRROLOPYRIMIDINE COMPOUND | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-04-24 | — | — | EP | disclosed |
| EP-3473626-A1 | PYRROLOPYRIMIDINE CRYSTAL FOR PREPARING JAK INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-04-24 | — | — | EP | disclosed |
| CN-109311891-A | The crystallization of Pyrrolopyrimidine compounds as JAK inhibitor | 正大天晴药业集团股份有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-109311893-A | Pyrrolopyrimidine compounds containing substituted cyclopenta | 正大天晴药业集团股份有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-109311892-A | Preparation method of chiral pyrrolopyrimidine compound | 正大天晴药业集团股份有限公司 | 2019-02-05 | — | — | CN | disclosed |
| WO-2017215627-A1 | PREPARATION METHOD FOR CHIRAL PYRROLOPYRIMIDINE COMPOUND | 正大天晴药业集团股份有限公司 | 2017-12-21 | — | — | WO | disclosed |
| EP-3235819-A1 | PYRROLOPYRIMIDINE COMPOUND | Centaurus BioPharma Co., Ltd. (CN) | 2017-10-25 | — | — | EP | disclosed |
| EP-3235819-A1 | PYRROLOPYRIMIDINE COMPOUND | Centaurus BioPharma Co., Ltd. (CN) | 2017-10-25 | — | — | EP | disclosed |
| CN-105777754-A | Pyrrolopyrimidine compound | 北京赛林泰医药技术有限公司 | 2016-07-20 | — | — | CN | disclosed |
| WO-2016095805-A1 | PYRROLOPYRIMIDINE COMPOUND | 北京赛林泰医药技术有限公司 | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072002-A1 | TREATMENT USE OF PYRROLOPYRIMIDINE COMPOUND, AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND | THPO, MPL, TPMT | JAK2 8/4885JAK1 29/4885JAK3 93/4885 |
| US-20230133735-A1 | USE OF PYRROLOPYRIMIDINE COMPOUND FOR TREATING HEMOPHAGOCYTIC SYNDROME | THPO, TSLP, SQSTM1 | JAK2 406/4885JAK1 1429/4885JAK3 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.